Heidelberg Pharma AG
Heidelberg Pharma AG (XETRA: HPHA) is trading at €2.44, about ₹266 at today's EUR/INR rate, as of 30 Sep 2026, 10:25 AM ET, down 3.17% today. Indian residents can buy Heidelberg Pharma from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
€2.30
Today's high
€2.46
52 week low
€2.30
52 week high
€3.34
HPHA opened at €2.46, closed previously at €2.52, and has traded between €2.30 and €3.34 over the past 52 weeks.
About
Heidelberg Pharma AG is a biopharmaceutical firm dedicated to oncology, with a specific emphasis on its innovative antibody-targeted amanitin conjugates (ATAC) technology. The company conducts its activities across Germany, various other European countries, the United States, and globally. Its primary drug candidate, HDP-101, is presently in Phase I/IIa clinical trials for individuals suffering from relapsed or refractory multiple myeloma. The pipeline also features several other ATAC compounds: HDP-102 is being developed for non-Hodgkin lymphoma; HDP-103 targets metastatic castration-resistant prostate cancer; HDP-104 is aimed at various tumor types; and HDP-XX addresses both solid and hematological tumors. Further development programs include MGTA-ATACs, designed for hematopoietic stem cells (HSCs) and conditioning treatments for blood cancers and genetic conditions, alongside TAK-ATACs for broader oncology use. Heidelberg Pharma's offerings extend to diagnostic and therapeutic antibodies. TLX250-CDx, a diagnostic antibody for imaging purposes, is in Phase III for renal cancer, Phase I for urothelial carcinoma (bladder cancer), and Phase II for triple-negative breast cancer. Additionally, TLX250 (girentuximab), a therapeutic antibody, is undergoing Phase II evaluation for patients with advanced clear cell renal cell carcinoma. The company's diverse portfolio is complemented by RHB-107, an oral serine protease inhibitor in Phase II/III studies for both COVID-19 and advanced cholangiocarcinoma, as well as LH011 for pancreatic cancer. A significant licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. grants the latter development and commercialization rights for HDP-101 and HDP-103 throughout Asia. Established in Ladenburg, Germany, in 1997, the company was formerly known as Wilex AG before rebranding to Heidelberg Pharma AG in October 2017.
Key statistics
Avg. volume
3.01K
Market cap
€114.15M
P/E Ratio
-3.49
Price-to-sales ratio
15.33
Enterprise value
€120.59M
Free cash flow yield
-23.61%
Debt-to-equity ratio
-0.00
Return on equity
387.26%
ROIC
-175.53%
Beta
0.77
Dividend yield
0.00%
Last dividend
€0.00
Financial overview
Revenue
€1.46M
Earnings per share
-€0.91
Free cash flow
-€31.73M
Net profit margin
-444.62%
Gross margin
85.90%
EBITDA
-€44.63M
Revenue growth
-78.72%
Similar securities
This is not an investment recommendation
How to buy Heidelberg Pharma from India
Indian residents can buy Heidelberg Pharma shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to EUR.
Search for Heidelberg Pharma and place an order
Find Heidelberg Pharma by name or by its ticker, HPHA, and choose an order type. Heidelberg Pharma trades 12:30 pm – 9:00 pm IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your Heidelberg Pharma position in EUR and INR. Heidelberg Pharma pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in Heidelberg Pharma from India
Trading and taxes when buying Heidelberg Pharma from India
Trading and limits
- Trading hours
- 9:00 am – 5:30 pm CET
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneHeidelberg Pharma does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
FAQs
Can Indian residents buy Heidelberg Pharma stock?
Yes. Heidelberg Pharma (HPHA) has been listed on XETRA since 2006, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to EUR. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
How much does one Heidelberg Pharma share cost in rupees?
One Heidelberg Pharma share is €2.44 — about ₹266 at an EUR/INR rate of 108.91 on 29 Sep 2026. Both the Heidelberg Pharma price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying Heidelberg Pharma from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
How are gains on Heidelberg Pharma shares taxed in India?
Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the EUR/INR rate on the purchase and the sale date, so the rupee move counts alongside the Heidelberg Pharma price. Paasa issues a capital-gains statement for your return.
Does Heidelberg Pharma pay a dividend?
No. Heidelberg Pharma does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade Heidelberg Pharma from India?
XETRA trades 12:30 pm – 9:00 pm IST in Indian time. The window shifts to 1:30 pm – 10:00 pm IST when Germany is on standard time. Orders can only execute during that window.
Do I have to declare Heidelberg Pharma shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Heidelberg Pharma holding, its cost and its closing value.
How do I sell Heidelberg Pharma and bring the money back to India?
You sell during market hours (12:30 pm – 9:00 pm IST) and the proceeds settle in EUR in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.
Does the rupee rate affect what I make on Heidelberg Pharma?
Yes. Heidelberg Pharma is priced in EUR, so your rupee outcome combines the EUR move with the EUR/INR move between the day you remit and the day you convert back. Both directions are reflected in the capital-gains statement Paasa issues.